Vascular Biogenics Ltd.
NASDAQ:VBLT
0.156 (USD) • At close October 16, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.658 | 0.768 | 0.922 | 0.562 | 0.585 | 13.864 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.104 | 0.365 | 0.394 | 0.163 | 0.235 | 0.34 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0.554 | 0.403 | 0.528 | 0.399 | 0.35 | 13.524 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.842 | 0.525 | 0.573 | 0.71 | 0.598 | 0.975 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 21.653 | 22.695 | 19.656 | 15.47 | 15.94 | 17.77 | 12.447 | 11.198 | 10.974 | 13.508 | 10.572 |
| General & Administrative Expenses
| 11.754 | 7.704 | 5.355 | 4.828 | 5.15 | 5.797 | 3.786 | 3.639 | 3.771 | 2.409 | 1.885 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0.397 | 0.562 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 11.754 | 7.704 | 5.355 | 4.828 | 5.547 | 6.359 | 3.786 | 3.639 | 3.771 | 2.409 | 1.885 |
| Other Expenses
| 0 | 0 | 0 | 0.115 | 0.07 | 0 | 0.042 | 0.034 | 0.033 | 0.043 | 0.012 |
| Operating Expenses
| 33.407 | 30.399 | 25.011 | 20.413 | 21.557 | 24.179 | 16.275 | 14.871 | 14.778 | 15.96 | 12.469 |
| Operating Income
| -32.853 | -29.996 | -24.483 | -20.014 | -21.207 | -10.655 | -16.275 | -14.871 | -14.778 | -15.96 | -12.469 |
| Operating Income Ratio
| -49.929 | -39.057 | -26.554 | -35.612 | -36.251 | -0.769 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.549 | 0.076 | 0.258 | 0.557 | -0.122 | 0.209 | 0.022 | -0.101 | -0.29 | 0.213 | 0.022 |
| Income Before Tax
| -32.304 | -29.92 | -24.225 | -19.457 | -20.458 | -10.138 | -16.002 | -14.888 | -17.407 | -17.37 | -12.225 |
| Income Before Tax Ratio
| -49.094 | -38.958 | -26.274 | -34.621 | -34.971 | -0.731 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0.085 | -1.212 | 0.105 | 0.313 | -0.749 | -0.517 | -0.273 | 0.017 | 2.629 | 1.41 | -0.244 |
| Net Income
| -32.219 | -28.708 | -24.33 | -19.77 | -20.458 | -10.138 | -16.002 | -14.888 | -17.407 | -17.37 | -12.225 |
| Net Income Ratio
| -48.965 | -37.38 | -26.388 | -35.178 | -34.971 | -0.731 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.42 | -0.41 | -0.56 | -0.55 | -0.62 | -0.37 | -0.64 | -0.73 | -3.09 | -1.44 | -1.01 |
| EPS Diluted
| -0.42 | -0.41 | -0.56 | -0.55 | -0.62 | -0.37 | -0.64 | -0.73 | -3.09 | -1.44 | -1.01 |
| EBITDA
| -31.161 | -29.876 | -22.926 | -17.43 | -19.929 | -10.708 | -16.167 | -14.648 | -14.353 | -16.004 | -12.294 |
| EBITDA Ratio
| -47.357 | -38.901 | -24.866 | -31.014 | -34.067 | -0.772 | 0 | 0 | 0 | 0 | 0 |